ARC9 Labs™ — Addiction Recovery Cascade Platform

Licensing Prospectus | IP Boardwalk Confidential Overview

A New Framework for Addiction Recovery
ARC9 Labs™ introduces a new therapeutic architecture for addiction recovery—built from the biological terrain upward.
Rather than sedating, substituting, or suppressing, the ARC9 approach supports the body’s innate recalibration systems, helping to reduce withdrawal stress, stabilize neurochemical function, and restore systemic resilience through non-pharmaceutical means.

URL: www.arc9labs.com

Platform Overview
At the core of the ARC9 Platform is a protected modeling environment (ARCMap™) that informs the design of adaptive recovery protocols.
This environment enables phase-structured formulation design and compound synergy modeling across diverse recovery profiles—while keeping all computational logic fully confidential.

Each ARC9 stack is:

• Phase-tuned to correspond with neurochemical and metabolic recovery stages

• Composed solely of FDA-recognized GRAS ingredients within a systems-biology framework

• Structured for resilience and withdrawal-mitigation without reliance on controlled substances or replacement therapy

• Developed under trade-secret protocols that preserve intellectual property while ensuring regulatory compatibility

This design establishes a clinically informed yet regulatory-safe path for pre-commercial engagement and future trial alignment.

Modeled Clinical Logic Without Clinical Risk
ARC9 employs an advanced internal modeling framework to simulate physiologic recovery dynamics across multiple substance classes.
While the platform has not undergone formal FDA evaluation, its methodology offers the predictive structure and safety insight necessary for confident pre-clinical positioning.
All modeling data, parameters, and validation cycles remain confidential; external partners interact only with summarized scenario outcomes and verified safety envelopes.

Licensing-Ready Formulation
ARC9 Protocol: Terrain Reset Stack (ARC9-TRS)

• Multi-phase formulation encompassing stabilization, restoration, and recalibration stages

• Utilizes GRAS-classified compounds targeting neurochemical recovery, oxidative balance, and system resilience

• Designed for deployment in DTC, clinical-adjunctive, or wellness contexts under licensing control

Pipeline Formulations in Refinement

• ARC9-A – Alcohol Recovery Module

• ARC9-B – Benzodiazepine Discontinuation Module

• ARC9-M – Stimulant Recovery Module

• ARC9-P – Polysubstance Stabilization Module

Each adheres to the same adaptive systems logic and is advancing through confidential modeling protocols.

Why It Matters

• Clinically modeled logic, commercially deployable platform – bridges the gap between academic modeling and market-ready application.

• Non-pharmaceutical, non-addictive architecture – enables safe deployment without controlled substances or dependency cycles.

• Regulatory foresight and IP flexibility – operates within GRAS standards while retaining pathways to formal clinical development.

ARC9 represents a terrain-first approach to addiction recovery—integrating biological restoration, data-governed design, and ethical therapeutic scaffolding.

Regulatory & IP Status

• All formulations constructed exclusively from GRAS-designated ingredients.

• ARCMap™ modeling framework and phase-design logic protected under trade-secret and IP development protocols.

• Product naming and stack identities filed or reserved under trademark designation.

Next Steps
Qualified partners may request a private briefing through the IP Boardwalk partner channel.
Licensing models include exclusive, semi-exclusive, and co-development tracks, with technical details available under NDA.

For inquiries or to initiate discussion, contact licensing@ipboardwalk.com.